ClinPGx Blog (Page 37)

Sign in Subscribe

More issues

CPIC Publishes Their Guideline Development Process

In Current Drug Metabolism, the Clinical Pharmacogenetics Implementation Consortium (CPIC) has defined the standardized operating procedures undertaken for each guideline written. Outlined in the publication is how gene-drug relationships are initially assessed for a potential guideline, how a writing committee with experts in the subject is established, the gathering and

CPIC guidelines for CYP2D6 genotypes and codeine therapy: 2014 Update

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published updates to the guidelines for the use of genetic test results for cytochrome P450-2D6 (CYP2D6) in codeine dosing. The 2014 update is now available online, as an accepted article preview.Alternate analgesics are recommended for CYP2D6 ultrarapid and poor metabolizers. Label recommended

The Genetics/Genomics Competency Center (G2C2) adds a new PGx section

The Genetics/Genomics Competency Center (G2C2) is a free, online resource that provides a collection of high quality educational materials for self-directed learning in genetics or genomics. It is targeted toward health care professionals such as genetic counselors, nurses, physician assistants and pharmacists. The educational information presented consists of journal

Pharmacodynamic pathways for drugs that lower uric acid levels

Unlike other animals, humans and apes have lost the ability to break down uric acid. High uric acid levels (hyperuricemia) can result in gout and kidney failure, and are a symptom of Tumor Lysis Syndrome experienced by some cancer patients. Two new PharmGKB pathways describe the mechanism of action of

Mixed Results for Genotype-guided Warfarin Dosing - Update

Update: New perspective piece from the New England Journal of Medicine The December 12 issue of the New England Journal of Medicine includes a perspective piece discussing the recent trial results on coumarin dosing. This article, Pharmacogenetics and Coumarin Dosing — Recalibrating Expectations, by Zineh et al from the Food and

(Untitled)

PharmGKB is looking to fill a Scientific Curator position on our team. Below is a description of the responsibilities of a curator at PharmGKB. To apply, search for Scientific Curator - 61462 under Staff Positions at jobs.stanford.edu · Read pharmacogenomic experimental literature, analyzing articles for details about gene variant-drug

Mixed Results for Genotype-guided Warfarin Dosing

Update (12/17/2013):New perspective piece from the New England Journal of Medicine The December 12 issue of the New England Journal of Medicine includes a perspective piece discussing the recent trial results on coumarin dosing. This article, Pharmacogenetics and Coumarin Dosing — Recalibrating Expectations, by Zineh et al from

Controversy over the PGx of Cisplatin-Induced Hearing Loss in children

Hearing loss is a common side effect in cancer patients treated with cisplatin, with significant effects on quality of life. Age, dosage, cranial irradiation and concomitant vincristine use are all established risk factors for cisplatin ototoxicity. However, there is debate surrounding genetic variants associated with risk and the clinical utility

PharmGKB Drug Labels: Description, Update and New Features

PharmGKB has recently added new information to drug label entries, standardized the annotations, and updated the website display. The overview page for drug labels contains high level information about each label at a glance, including: * Whether the drug label is currently on the FDA's Table of Pharmacogenomic Biomarkers

PG&G publication: Mycophenolic acid Pathway

Mycophenolic acid (MPA) is an immunosuppressive agent used to prevent rejection in organ transplantation. We recently have published this pathway summary in the Pharmacogenetics and Genomics Journal.The article and included figure describe the metabolism of MPA and its prodrug mycophenolate mofetil. MPA is a noncompetitive, selective and reversible inhibitor